Rare Disease Meeting Highlights FDA’s RDCA-DAP Research Resource

A recent rare disease meeting brought together more than 400 attendees to introduce the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) resource. The tool is intended to facilitate research into rare disease by streamlining data collection and analysis.

NORD’s Chief Medical and Scientific Officer Ed Neilan remarks,”Patient-owned data collected by patient groups are less likely to get stuck in a silo​,” adding, “Of the over 7,000 estimated rare diseases, more than 90% have no FDA-approved treatment, and currently the attention of the pharmaceutical industry is on 100 or 200 of these rare diseases. RDCA-DAP may bring attention to rare diseases that might otherwise remain relatively neglected​.” Read more here.

(Source: Jenni Spinner, Outsourcing-Pharma, 9/16/21)